Cytokine News and Research

RSS

Aged immune cells may drive memory decline by releasing a brain-aging protein

A preclinical mouse study in Immunity suggests that aged circulating CD8+ T cells can disrupt hippocampal function and impair learning and memory. The findings point to granzyme K, a secreted factor linked to age-associated CD8+ T cells, as a potential target for restoring aspects of cognition in aging.

17 May 2026

New guidelines for identifying and treating high-risk IEC-HS patients

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering durable responses for patients with otherwise refractory disease. However, its clinical success is accompanied by a spectrum of immune-related toxicities, which remain a major challenge in practice.

15 May 2026

Researchers develop pH and redox-sensitive systems to reduce immunotherapy toxicity

Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small subset of patients benefit. Many solid tumors remain "cold," characterized by poor immune cell infiltration and resistance to immune checkpoint blockade (ICB).

15 May 2026

How Andes virus super-spreaders reveal the risk behind the MV Hondius hantavirus cluster

A 2020 NEJM study of the 2018 to 2019 Epuyén outbreak showed that Andes virus spread from one zoonotic introduction into four generations of human infection, causing 34 cases and 11 deaths. The findings are newly relevant after WHO reported an ANDV cluster linked to the MV Hondius cruise ship, where close indoor exposure may have enabled onboard human-to-human transmission.

14 May 2026

Implantable cytokine factories show promise against advanced ovarian cancer

Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step toward clinical reality.

12 May 2026

Breathing polluted air before surgery may worsen recovery outcomes

Findings indicate that elevated fine PM exposure before surgery correlates with higher postoperative complication rates, urging further research in this area.

11 May 2026

Manuka honey eye drops outperform artificial tears for dry eye relief

A clinical study reveals Manuka honey eye drops significantly improve dry eye symptoms after cataract surgery, outperforming traditional treatments.

1 May 2026

Food timing may shape how T cells respond to infection and therapy

Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic capacity, cytokine production, and persistence after activation. The study identifies triglyceride-rich chylomicrons as key drivers of this effect, suggesting nutritional timing may matter for immune monitoring, vaccination research, and cell-therapy manufacturing.

30 Apr 2026

New CAR T cell design boosts persistence and reduces toxicity

CAR T-cell therapy has transformed the treatment of hematologic malignancies, yet many patients do not achieve lasting benefit – often because the infused cells fail to expand or persist.

30 Apr 2026

Antibiotic minocycline shows potential for treating panic disorder symptoms

A study supported by FAPESP shows that small doses of the antibiotic minocycline may help treat panic disorder.

30 Apr 2026

From killers to strategists: CAR T cells enter their multifunctional era

A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.

30 Apr 2026

Scientists identify specialized cells that trigger bone marrow cavity growth

Bone marrow is the spongy tissue located within the hollow center of bones, serving as the primary site for the continuous production of red blood cells, platelets, and white blood cells.

28 Apr 2026

Hyperbaric oxygen therapy shows dual effects in glioblastoma treatment

Glioblastoma remains a highly challenging malignancy with a pronounced tendency for recurrence. The hypoxic microenvironment is a key contributor to its therapy resistance.

23 Apr 2026

Pinecone-inspired conduit enables suture-free repair of nerve injuries

As the authors detail, PNI is a prevalent neurological condition that often causes permanent sensory and motor dysfunction, severely impairing patient's quality of life.

21 Apr 2026

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

21 Apr 2026

Trial shows safety of novel KIR-CAR T therapy in solid tumors

An innovative type of CAR T cell therapy, called KIR-CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine patients with advanced ovarian cancer, mesothelioma or cholangiocarcinoma (bile duct cancer), according to an early report from an ongoing Phase I dose-escalation clinical trial.

20 Apr 2026

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026